INTRODUCTION
Atrial fibrillation (AF) is the most prevalent form of arrhythmia, involving about 1-2% of the population in industrialized countries [1] . Its prevalence increases with age, reaching values above 5% in the over 65 years old, and of 9% in octogenarians [2] . form of arrhythmia [1] , and in these patients, they tend to be more severe than in non-arrhythmic patients [5] . About 40% of stroke survivors presents moderate to severe disability; applying these rates to the prevalent population, it has been calculated that around 384,000 are not autonomous in Italy due to stroke, and this figure is expected to rise up to 440,000 by 2020 [6] . Therapeutic goals in the management of AF patients include symptom control, but also the prevention of thromboembolic complications, stroke in primis. This was traditionally pursued with the administration of vitamin K antagonists (VKA), or with antiplatelet agents, mainly aspirin, in subjects intolerant or contraindicated to VKAs [7] . Apixaban, a direct and selective coagulation factor Xa inhibitor, which is associated with a more favorable risk/benefit ratio than VKA and aspirin [8, 9] is facing the launch on the market for the thromboembolic prevention in non-valvular AF (NVAF, about 70% of all FA cases), with reimbursement restrictions: NVAF with both CHA 2 DS 2 -VASc ≥ 1 1 and HAS-BLED > 3 2 , or TTR < 70% or objective difficulties in measuring INR [10] . The objective of the present analysis is the evaluation of the cost/effectiveness of the use of apixaban in the prevention of thromboem- bolic events in the indicated Italian population of patients with NVAF, as compared with the standard of care (warfarin for the suitable population, aspirin for the remaining).
METHODS
The analysis is conducted as a simulation study, performed through the adaptation of a previously published international model [11, 12] simulated using epidemiological, clinical practice and unit costs pertinent to the Italian setting. The model is designed to reproduce the experience of a cohort of NVAF patients of user defined features, alternatively treated with the compared therapeutic options. During the lifetime simulation, events and consumed resources from the Italian National Health System perspective are recorded by the model; main clinical outcomes monitored are ischemic and hemorrhagic stroke, systemic thromboembolism, bleeds (both major and clinically relevant minor), cardiovascular hospitalizations, and death. Summary effectiveness indicators are overall survival, expressed in life years (LY), and expected quality-adjusted survival, expressed in quality-adjusted life years (QALYs).
Model structure
The model is designed as a decision tree with Markov chains as branches; the experience of a NVAF patient is discretized in 17 possible and mutually exclusive health states (Figure 1) . Transitions among health states are determined by probability matrices derived from the relevant literature as detailed elsewhere [11] . At the end of each 6 week cycle, patients can stay in the current health state, or experience a clinical event and transition to the corresponding state; some events only imply a resource consumption and a temporary change in the utility (quality of life index), whilst others -i.e. stroke, myocardial infarction (MI), and systemic embolism -also modify the chance of incurring in further events. Stroke survivors distribute among subsequent health states basing on the assigned severity distribution of the specific event. Following a major bleeding, patients may continue to receive the initial anticoagulant, or switch to a second line treatment, associated with specific clinical event risks.
Population
The simulation is run on two cohorts (Table I) : the first (base-case) reproducing clinical and demographic features of the AVERROES [9] and ARISTOTLE [8] trial population, for the analysis of NVAF patients unsuitable and suitable for VKA therapy, respectively; the second those of a non-experimental population of NVAF patients studied by Olesen et al. [13] . In this cohort study, Olesen et al. assessed the individual risk factors composing the CHADS 2 and CHA 2 DS 2 -VASc score calculating the capability of the schemes to predict thromboembolism in a nationwide cohort of Danish real world patients.
Clinical outcomes rates
The effectiveness and safety profile of apixaban by VKA suitability reflects event rates recorded in the ARISTOTLE [8] and AVER-ROES trials [9] , integrated with patient-level data made available by Dorian et al. (Table  II) . ARISTOTLE was an international, multicentre, double-blind, double-dummy, placebo-controlled, randomised controlled trial that compared apixaban with warfarin in 18,201 adults with atrial fibrillation and at least one additional risk factor for stroke, assessed by CHADS 2 criteria. Apixaban was associated with a significantly lower rate of stroke and systemic embolism than warfarin. When strokes were analysed separately, apixaban was associated with a significant reduction in hemorrhagic stroke compared with warfarin. Episodes of fatal or disabling stroke were significantly lower in the apixaban arm. The safety analyses point out as apixaban resulted in significantly fewer bleeding events than warfarin for all of the major bleed types and clinically relevant non-major bleeding events. AVERROES study was an international, multicentre, double-blind, double-dummy, placebo-controlled, randomised controlled trial that compared apixaban with aspirin in 5,599 adults with atrial fibrillation and at least 1 additional risk factor for stroke for whom treatment with warfarin was unsuitable or the patients were unwilling to take it. Apixaban reduced the rate of stroke and 
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Hemorrhagic strokes (HS) are determined as a treatment-specific percentage of ICHs; similarly, their severity distribution, again expressed in terms of mRS, is treatment-specific. IS and HS survivors are at risk of recurrence: this is modelled according to a real-life registry indicating a cumulative incidence of 4.1 and 3.0 per 100 patient-years, respectively [16] ; the severity distribution of recurrent strokes is conditional on the severity of the first stroke, as observed in ARISTOTLE and AVERROES.
As with IS and ICH, the model accounts for increasing MI risk with higher ages by applying an HR of 1.30 per decade [17] . MI case fatality rates applied in the simulation are specific for gender (10.8% in men and 15.6 for women), differently than for SE (9.4%) [18] .
systemic embolism compared with aspirin; rates of fatal or disabling stroke were also lower in patients who received apixaban. When strokes were considered as a separate outcome, apixaban decreased the rates of ischaemic stroke compared with aspirin but did not statistically significantly decrease the rates of hemorrhagic stroke. Increasing age is associated with higher ischemic stroke (IS) risk; in the model, this is accounted for by applying a HR of 1.4 per decade [14] . Severity distribution of ISs is classified according to the modified Rankin scale (mRS -mild 0-2; moderate 3-4; severe 5 and fatal 6) specific to the anticoagulant (AC) treatment and was derived from published literature (Table II) . Similarly, the model accounts for age-related increase in Intra Cranial Hemorrhages (ICH) risk by applying a 1.97 HR per decade [15] . for each severity category within ischemic and hemorrhagic strokes, the mean long-term maintenance cost has been approximated to the monthly cost recorded in the second semester; the costs for the acute phase correspond to the sum of the corresponding DRG tariff [32] and the difference between the costs accrued in the first and second follow-up semester. For acute and long-term MI management, cost data are elaborated basing on three-year follow-up data reported for Italian MI survivors [33] . The costs attributed to the other clinical events considered are equaled to the During the simulation, patients may discontinue treatment, either completely, or by switching to another AC regimen, as a consequence of clinical events incurred, or for other reasons, as described on Dorian et al. [11] and Lip et al. [12] . Besides the already described case fatality rates for stroke, bleeding, and MI, the population is subjected to a background mortality derived from ARISTOTLE for the duration of the trial follow-up; given the lack of sound comparative mortality rates, the same background mortality has been applied to all NOACs.
Beyond the trial duration, mortality is projected based on Gompertz distributions fitted on Italian age-and gender-specific population rates [19] , corrected for the HRs associated to AF, MI, stroke, and SE, as shown in Table III .
Utility
Baseline utility assigned to the simulated population derives from a preference study conducted on AF patients [25] . The model accounts for reduced preference for warfarin and ASA administration, as reported in Gage et al. [26] ; temporary disutilities are assigned to patients experiencing clinical events, as shown in Table IV .
Costs
Costs are evaluated from the perspective of the National Health System (SSN); accordingly, only direct health care costs are considered: -Drug acquisition costs, at negotiated net prices [27] (Table V) ; -Routine visits [28] for all treated patients and INR monitoring for warfarin treated patients, basing on data reported by Pengo in 2011 [29] and Mennini in 2012 [30] ; -Acute event management (strokes, bleeds, myocardial infarction, and other CV hospitalizations); -Long-term post-event management for stroke, MI, and SE; -Other health care costs associated with AC management (Table VI) 
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The effect of parameter uncertainty on the results is assessed by probabilistic sensitivity analyses (PSA), in which the model is re-evaluated with 2000 sets of parameter values sampled from appropriate distributions. The influence of single parameters on the results is evaluated with a series of one-way deterministic sensitivity analyses (DSA), in which the model is re-calculated using extreme parameter values, corresponding to the lower and upper limits of the 95% confidence interval; when this was unavailable from the original data, it has been calculated assuming a SEM equaling 25% of the mean. In incremental cost/effectiveness analyses, costs and benefits accruing after the first year are discounted at a 3.5% annual rate.
corresponding DRG-based tariff [32] paid to the hospitals by the SSN.
Other AC related costs considered are related to dyspepsia management (€ 71.46/year [34] , rates of dyspepsia from ARISTOTLE for apixaban and warfarin). All historical cost data have been actualized to 2013 values using official indices [19] .
Incremental cost/ effectiveness analysis
Lifetime results from the simulation are presented as incremental cost/effectiveness and incremental cost/utility ratios, i.e. as the ratio of the difference in costs over the difference in life years and quality-adjusted life years, respectively. Figure 3) . Probabilistic sensitivity analysis substantially confirms the findings of the main analysis, as shown in Figure 4 representing the distribution of the 2000 ICER estimates of the PSA. Apixaban is expected to be a better choice than warfarin for any WTP above about 10,000 €/QALY gained, with probabilities of being cost-effective of 93% and 96%, for the conventional WTP thresholds of 20,000 and 30,000 €/QALY gained, respectively. Cor- Figure 5 . Figure 2 , showing the impact of single parameters on the estimated ICERs in order of decreasing magnitude of effect. The most
These data lead to very favourable pharmacoeconomic indicators, which suggest that the introduction of apixaban in the treatment of Italian NVAF patients represents an efficient allocation of health care resources, as compared to the treatment which are currently the standard of care. Furthermore, the calculated cost/effectiveness neglects an aspect which has the potential to increase the convenience of apixaban: it is the first and currently only NOAC to have demonstrated efficacy also in VKA-unsuitable patients, and will therefore be considered as relevant option by the decision makers in this specific subpopulation. This may avoid the discomfort, risk, and cost of treatment failures in patients who would otherwise be started on less specific treatments, or with warfarin, with the subsequent need for therapeutic revision, in case VKA-unsuitability should emerge.
In conclusion, the clinical data and expected pharmacoeconomic performance of apixaban is favourable, and it can be considered a welcome new entry in the therapeutic armamentarium at the disposal of the physician caring for NVAF patients in Italy.
responding percentages for the comparison with aspirin in the VKA-unsuitable population are 95% and 98% ( Figure 5 ).
The substantial stability of model results is further confirmed by the analysis of apixaban vs. warfarin conducted on the cohort reproducing the clinical features and demographics of the real world population described in [13] : mean incremental QALYs and costs are both estimated slightly lower (0.15 vs. 0.20 and 900 vs. 1100 €, respectively), but the resulting ICER is comparable -about 6,200 €/ QALY gained.
CONCLUSIONS
In NVAF patients unsuitable for VKA treatment, studied in the AVERROES trial, apixaban compared favourably with ASA, reducing the incidence of stroke or systemic embolism, without increasing the incidence of bleedings (ICH included). In the ARIS-TOTLE trial, apixaban was clearly superior to warfarin in preventing stroke or systemic embolisms, with a concomitant reduction in bleedings (including haemorrhagic stroke) and more importantly in all-cause mortality.
